174 related articles for article (PubMed ID: 38344133)
1. Why Do I Get Side Effects? Personalized (N-of-1) Trials for Statin Intolerance and the Nocebo Effect.
Howard JP; Wood FA; Francis DP
Harv Data Sci Rev; 2022; 2022():. PubMed ID: 38344133
[TBL] [Abstract][Full Text] [Related]
2. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs.
Herrett E; Williamson E; Brack K; Perkins A; Thayne A; Shakur-Still H; Roberts I; Prowse D; Beaumont D; Jamal Z; Goldacre B; van Staa T; MacDonald TM; Armitage J; Moore M; Hoffman M; Smeeth L
Health Technol Assess; 2021 Mar; 25(16):1-62. PubMed ID: 33709907
[TBL] [Abstract][Full Text] [Related]
3. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
Krishnamurthy A; Bradley C; Ascunce R; Kim SM
Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
[TBL] [Abstract][Full Text] [Related]
4. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.
Howard JP; Wood FA; Finegold JA; Nowbar AN; Thompson DM; Arnold AD; Rajkumar CA; Connolly S; Cegla J; Stride C; Sever P; Norton C; Thom SAM; Shun-Shin MJ; Francis DP
J Am Coll Cardiol; 2021 Sep; 78(12):1210-1222. PubMed ID: 34531021
[TBL] [Abstract][Full Text] [Related]
5. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
6. The nocebo effect in the context of statin intolerance.
Tobert JA; Newman CB
J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103
[TBL] [Abstract][Full Text] [Related]
7. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.
Herrett E; Williamson E; Beaumont D; Prowse D; Youssouf N; Brack K; Armitage J; Goldacre B; MacDonald T; Staa TV; Roberts I; Shakur-Still H; Smeeth L
BMJ Open; 2017 Dec; 7(12):e016604. PubMed ID: 29197834
[TBL] [Abstract][Full Text] [Related]
8. New insights into managing symptoms during statin therapy.
Robinson JG
Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with statin intolerance.
Martirossian AN; Goldberg AC
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101714. PubMed ID: 36345572
[TBL] [Abstract][Full Text] [Related]
10. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
11. [How to cope with the nocebo effects of statins?].
Lafeber M; Evers AWM; Klok FA
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36920298
[TBL] [Abstract][Full Text] [Related]
12. Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence.
Tudor K; Brooks J; Howick J; Fox R; Aveyard P
BMJ Open; 2020 Feb; 10(2):e033070. PubMed ID: 32051312
[TBL] [Abstract][Full Text] [Related]
13. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.
Herrett E; Williamson E; Brack K; Beaumont D; Perkins A; Thayne A; Shakur-Still H; Roberts I; Prowse D; Goldacre B; van Staa T; MacDonald TM; Armitage J; Wimborne J; Melrose P; Singh J; Brooks L; Moore M; Hoffman M; Smeeth L;
BMJ; 2021 Feb; 372():n135. PubMed ID: 33627334
[TBL] [Abstract][Full Text] [Related]
14. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
Feys F; Bekkering GE; Singh K; Devroey D
Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
[TBL] [Abstract][Full Text] [Related]
15. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.
Finegold JA; Manisty CH; Goldacre B; Barron AJ; Francis DP
Eur J Prev Cardiol; 2014 Apr; 21(4):464-74. PubMed ID: 24623264
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
17. Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials.
Kraut R; Wierenga F; Molstad E; Korownyk C; Perry D; Dennett L; Garrison S
PLoS One; 2023; 18(12):e0295857. PubMed ID: 38128013
[TBL] [Abstract][Full Text] [Related]
18. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Newman CB; Preiss D; Tobert JA; Jacobson TA; Page RL; Goldstein LB; Chin C; Tannock LR; Miller M; Raghuveer G; Duell PB; Brinton EA; Pollak A; Braun LT; Welty FK;
Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):e38-e81. PubMed ID: 30580575
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
